{"url_path":"/sec/fbrx/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 Legal Proceedings","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-215862-index.html","accession_number":"0001193125-26-215862","cik":"0001419041","ticker":"FBRX","issuer_name":"Forte Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-215862-index.html","primary_entity_key":"0001419041","primary_entity_name":"Forte Biosciences, Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 1: Legal Proceedings\n\nFor a description of our pending legal proceedings, see Note 6 - Commitments and Contingencies of the notes to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Form 10-Q, which is incorporated herein by reference. As of the filing of this report, no legal proceedings are pending against us that we believe individually or collectively are likely to have a materially adverse effect upon our financial condition, results of operations, or cash flows"}